Therapeutic Asset Ratings
191 results matching 1 filter
129,767 assets · 8,707 sponsors · 3,128 indications
Methodology v0.2
Filters
1
Highest Rated
Advanced Phase
Alphabetical
Recently Updated
Asset
Sponsor
Phase
Rating
pf-08046054
Endometrial Carcinoma
Seagen, a wholly owned subsidiary of Pfizer
P1
C
(37)
Phn-010
Endometrial Carcinoma
Pheon Therapeutics
P1
C
(37)
Phst001
Endometrial Carcinoma
Pheast Therapeutics
P1
C
(37)
PIMITESPIB
Endometrial Carcinoma
Brown University
P1
C
(37)
rad301
Endometrial Carcinoma
Radiopharm Theranostics, Ltd
P1
C
(37)
Rgt-490
Endometrial Carcinoma
Regor Pharmaceuticals Inc.
P1
C
(37)
Seclidemstat
Endometrial Carcinoma
HonorHealth Research Institute
P1
C
(37)
Slv-154
Endometrial Carcinoma
Solve Therapeutics
P1
C
(37)
Stro-004
Endometrial Carcinoma
Sutro Biopharma, Inc.
P1
C
(37)
TH19P01-DOCETAXEL
Endometrial Carcinoma
Theratechnologies
P1
C
(37)
Torl-1-23
Endometrial Carcinoma
TORL Biotherapeutics, LLC
P1
C
(37)
Xmab541
Endometrial Carcinoma
Xencor, Inc.
P1
C
(37)
Cosibelimab
Endometrial Carcinoma
Checkpoint Therapeutics, Inc.
P1
C
(36)
177lu-rad204
Endometrial Carcinoma
Radiopharm Theranostics, Ltd
Early P1
C
(34)
Montelukast
Endometrial Carcinoma
University of South Florida
Early P1
C
(34)
DEXAMETHASONE
Endometrial Cancer
Seoul National University Hospital
N/A
D
(28)
Showing 176 to 191 of 191 assets
Previous
Page 8 of 8
Next
